Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Belay Diagnostics
Clinicians Report That Summit 2.0™ Influenced Clinical Decision-Making in 86% of Cases; 96% Stated They Would Order the Test Again
July 21, 2026
Belay Announces Update to NCCN Guidelines to Recommend CSF-based Genomic Profiling in Biopsy Infeasible High-Grade Gliomas
June 17, 2026
Belay Diagnostics Summit™ Informed Clinical Decisions in 93% of Cases in Large Real-World CNS Study
May 6, 2026
CSF Liquid Biopsy May Help Clarify Inconclusive Leptomeningeal Disease Cases, Study Finds
April 14, 2026
Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study
March 24, 2026